Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The ...

New weight management drugs could be used to create a global metabolic health revolution and improve longevity, if investment ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 receptor agonist. High-profile endorsements, including from Elon Musk, have ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

In short, semaglutide can help people with diabetes improve their blood sugar and lose weight. Higher doses seem to work ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School ...

As medications like 'Wegovy' and 'Ozempic' (GLP‑1 receptor agonists) become more common in weight‑loss strategies, US ...

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and ...